Europe Virology Market

The size of the Virology Market in Europe is predicted to hike at a promising CAGR from 2023 to 2028.

Virology refers to the science of viruses, which are sub microscopic, parasitic particles of genetic material in a protein coat, and virus-like agents. Virology mainly aims at the structure, classification, and evolution of viruses, their means of infection and exploitation of host cells for reproduction, their interaction with the host body physiology and immunity, the procedures to isolate and culture them, and their use in research and therapy. Virology is considered as a subfield of microbiology.

The significant drivers are various treatments and diagnostic processes that use virology applications. Increasing virology applications in gene therapy, phage therapy, formulation of vaccines, etc. are also expected to boost the market. Increasing Public awareness programs conducted worldwide on flu, zika virus, STDs, AIDS, and Ebola virus are also key factors driving the market. However, quality and safety standards are a longstanding challenge, and stringent approval processes for antiviral drugs may limit this industry's growth.

This market research report on the Europe Virology Market has been segmented and sub-segmented into the following categories:

• By Type: Diagnosing Test, Viral Infection Controlling Methods, Antiviral Chemotherapy and Interferons
• By Application: Skin and Soft Tissue Infections, Respiratory Tract Infections, GI Tract Infections, Urinary Tract Infections, Eye Infections, CNS Infections, Sexually Transmitted Diseases, and Perinatal Infections
• By End-User: Hospitals, Clinics, Laboratories, Diagnostic Centres, Blood Banks, and Pharmacies
• By Country: United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, and Rest of Europe

Regionally, Europe is projected to sustain its spot as the second-largest virology market globally. During the forecast period, Europe is forecasted to record the highest CAGR, accredited by improved healthcare infrastructure, aided access to diagnostics, and the growing affordability of diagnostic tests for viral illnesses. Europe region had the highest CAGR owing to improved healthcare infrastructure, increasing access to diagnostics, and growing affordability of diagnostic tests for viral.

Boehringer Ingelheim Corporation, Merck and Co. Inc, GlaxoSmithKline plc, Abbott Laboratories, Novartis International AG, Siemens, Johnson & Johnson, AstraZeneca AB, and Roche are some of the key players in the Europe Virology market.